Nitrazepam

Quanterix sNfL Assay and Simoa Technology First to Measure Neuronal Injury in COVID-19 Patients’ Blood

Retrieved on: 
Wednesday, July 29, 2020
Other Health, Research, Pharmaceutical, Oncology, Mental health, Medical devices, Infectious diseases, Science, Cardiology, Biotechnology, Other Science, Health, Medical signs, Biomarkers, Biotechnology, Chemical pathology, Nitrazepam, Biology

However, experts caution that it could require years of study to fully understand the long-term effects of these symptoms.

Key Points: 
  • However, experts caution that it could require years of study to fully understand the long-term effects of these symptoms.
  • Harnessing the power of biomarkers to shed light on these scientific mysteries and improve testing precision is the collective missions at Quanterix and PPH.
  • Notably, all positive patients reported mild-to-moderate symptoms with recovery within one-to-three weeks and showed no or only minor neurological symptoms.
  • In patients with two sNfL measurements, sNfL levels were highly correlated.